Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

F. Ravandi, A. Pigneux, D. J. De Angelo, E. Raffoux, J. Delaunay, X. Thomas, T. Kadia, H. Kantarjian, J. Scheuenpflug, C. Zhao, W. Guo, B. D. Smith

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies'. Together they form a unique fingerprint.